Alkermes (ALKS) Other Non Operating Income (2010 - 2026)
Alkermes' (ALKS) quarterly Other Non Operating Income came in at $352000.0 in Q2 2026, down 54.35% year-over-year from $771000.0 in Q2 2025, and up 127.22% quarter-over-quarter from -$1.3 million in Q1 2026.
Analysis
Alkermes (ALKS) Other Non Operating Income (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Other Non Operating Income for 17 consecutive years, with $352000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Non Operating Income fell 54.35% year-over-year to $352000.0 in Q2 2026; TTM through Jun 2026 was $3.7 million, a 53.12% decrease from a year earlier, with the FY2025 full-year figure at $7.0 million, down 10.75% from the prior year.
- Other Non Operating Income was $352000.0 for Q2 2026 at Alkermes, up from -$1.3 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $5.4 million in Q4 2023 and troughed at -$5.4 million in Q4 2022.
- A 5-year average of $877500.0 and a median of $455000.0 in 2024 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 915.32% in 2022, down 746.18% in 2022.
- Over 5 years, Other Non Operating Income stood at -$5.4 million in 2022, then soared by 199.65% to $5.4 million in 2023, then declined by 6.5% to $5.0 million in 2024, then slipped by 1.87% to $4.9 million in 2025, then sank by 92.86% to $352000.0 in 2026.
- The last three Other Non Operating Income figures came in at $352000.0 (Q2 2026), -$1.3 million (Q1 2026), and $4.9 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.50 Bn | 624.74 Bn | 17.26 Bn |
| 2 | AbbVie | 443.58 Bn | 437.01 Bn | 12.70 Bn |
| 3 | Merck | 365.15 Bn | 358.01 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.63 Bn | 258.94 Bn | 11.24 Bn |
| 5 | Pfizer | 158.52 Bn | 146.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.95 Bn | 43.95 Bn | - |
| 8 | Incyte | 25.37 Bn | 20.83 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.56 Bn | 18.90 Bn | 683.80 Mn |
| 10 | Alkermes | 7.57 Bn | 6.92 Bn | 397.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 352,000.00 |
| Mar 31, 2026 | -1.29 Mn |
| Dec 31, 2025 | 4.93 Mn |
| Sep 30, 2025 | -280,000.00 |
| Jun 30, 2025 | 771,000.00 |
| Mar 31, 2025 | 1.56 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Sep 30, 2024 | 558,000.00 |
| Jun 30, 2024 | 2.05 Mn |
| Mar 31, 2024 | 182,000.00 |
| Dec 31, 2023 | 5.37 Mn |
| Sep 30, 2023 | 149,000.00 |
| Jun 30, 2023 | -525,000.00 |
| Mar 31, 2023 | -39,000.00 |
| Dec 31, 2022 | -5.39 Mn |
| Sep 30, 2022 | -1.86 Mn |
| Jun 30, 2022 | 1.81 Mn |
| Mar 31, 2022 | 2.43 Mn |
| Dec 31, 2021 | 5.49 Mn |
| Sep 30, 2021 | 288,000.00 |